Nichi-Iko Pharmaceutical is off to a new start making the former Elmed Eisai its wholly owned subsidiary on April 1.…
BUSINESS
Oncolys in Talks with Checkpoint Drug Makers for Telomelysin: President
Tokyo-based biotech Oncolys BioPharma is in talks with several major drug makers that have immune checkpoint inhibitors in their portfolios for the possible out-licensing of its oncolytic virus telomelysin, President Yasuo Urata revealed on February 8. “We are aggressively exploring…
To read the full story
Related Article
BUSINESS
- Teva Takeda to Shutter 2 Factories in Shiga
April 24, 2019
- Boehringer Seeks Additional Indication for Ofev
April 23, 2019
- Nippon Kayaku Grabs Japan Rights to Lilly’s Soon-to-Launch Portrazza
April 23, 2019
- Banned Doping Substance Contamination on API Production Line: Sawai Report
April 23, 2019
- MSD Japan Chief Flags Re-Pricing for Keytruda, Says It’s “Heading into That Range”
April 22, 2019
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan is to not use its new cost-effectiveness assessment (CEA) scheme for reimbursement decisions - at least for now -…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…